ALMR: Q3 revenue rose 68%; major study wins supported higher FY26 guidance

What happened

Alamar Biosciences reported that third-quarter revenue grew 68% year over year and gross margin, the share of revenue left after direct costs, reached 61.5%, led by consumables. Wins for UK Biobank and GSK studies supported higher fiscal-year revenue guidance of $121M–$123M.

Confirmed

Global impact / market context

The reported growth and study wins point to stronger demand for Alamar’s consumables and study-related work. If that demand continues, higher sales could support revenue growth, while the 61.5% gross margin indicates how much revenue remains after direct costs to cover other expenses.

Analyst inference

The article provides company-specific figures but no detail on earlier guidance, revenue sources beyond consumables, cash available, or costs outside gross margin. Investors therefore cannot tell from this account alone whether growth is broad-based, recurring, or translating into stronger overall profits.

Analyst inference

What to watch

1. Compare reported revenue with the $121M–$123M fiscal-year guidance; results below that range could indicate that study-related demand did not continue as expected. Analyst inference
2. Look for updates on the UK Biobank and GSK study wins, including whether they lead to continuing consumables sales or only limited, one-time revenue. Analyst inference
3. Track revenue growth and gross margin in later quarters to assess whether consumables remain the leading contributor and whether direct costs rise alongside sales. Analyst inference

Evidence

• Original source link unavailable